Spero Therapeutics (NASDAQ:SPRO) Given "Overweight" Rating at Cantor Fitzgerald

Spero Therapeutics (NASDAQ:SPRO - Get Free Report)'s stock had its "overweight" rating reaffirmed by stock analysts at Cantor Fitzgerald in a research note issued on Friday,Benzinga reports.

Several other research analysts have also recently commented on SPRO. HC Wainwright lowered their price target on shares of Spero Therapeutics from $7.00 to $5.00 and set a "buy" rating for the company in a report on Monday, November 4th. TD Cowen upgraded shares of Spero Therapeutics from a "hold" rating to a "buy" rating in a research note on Tuesday, August 6th.

Spero Therapeutics Stock Down 5.6 %

NASDAQ:SPRO traded down $0.07 during trading hours on Friday, reaching $1.18. 465,359 shares of the stock were exchanged, compared to its average volume of 218,831. Spero Therapeutics has a twelve month low of $1.01 and a twelve month high of $1.89. The business has a 50-day moving average of $1.30 and a two-hundred day moving average of $1.37. The company has a market capitalization of $63.71 million, a price-to-earnings ratio of 3.75 and a beta of 0.63.

Hedge Funds Weigh In On Spero Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Virtu Financial LLC acquired a new position in Spero Therapeutics in the first quarter valued at $31,000. Acadian Asset Management LLC grew its stake in Spero Therapeutics by 121.8% during the 1st quarter. Acadian Asset Management LLC now owns 762,598 shares of the company's stock worth $1,310,000 after buying an additional 418,742 shares during the last quarter. Murchinson Ltd. increased its position in Spero Therapeutics by 1.3% during the first quarter. Murchinson Ltd. now owns 873,910 shares of the company's stock worth $1,503,000 after buying an additional 11,210 shares during the period. Renaissance Technologies LLC lifted its stake in Spero Therapeutics by 14.2% in the second quarter. Renaissance Technologies LLC now owns 975,952 shares of the company's stock valued at $1,269,000 after buying an additional 121,492 shares during the last quarter. Finally, Vanguard Group Inc. boosted its holdings in shares of Spero Therapeutics by 0.6% in the first quarter. Vanguard Group Inc. now owns 1,653,432 shares of the company's stock valued at $2,844,000 after acquiring an additional 9,675 shares during the period. 25.60% of the stock is owned by institutional investors and hedge funds.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.